|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:businessModel
|
multinational
|
|
gptkbp:CEO
|
gptkb:Thomas_Glanzmann
|
|
gptkbp:competitor
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:CSL_Behring
Octapharma
|
|
gptkbp:country
|
gptkb:Spain
|
|
gptkbp:focus
|
clinical diagnostics
plasma-derived therapies
transfusion medicine
hospital pharmacy solutions
|
|
gptkbp:founded
|
1940
|
|
gptkbp:founder
|
José Antonio Grifols Roig
|
|
gptkbp:headquarters_location
|
gptkb:Barcelona,_Spain
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Grifols, S.A.
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
ES0171996087
|
|
gptkbp:legalForm
|
Sociedad Anónima
|
|
gptkbp:listedOn
|
gptkb:IBEX_35
gptkb:Madrid_Stock_Exchange
NASDAQ (as ADR)
|
|
gptkbp:market
|
global
|
|
gptkbp:netIncome
|
€271 million (2022)
|
|
gptkbp:notableAcquisition
|
gptkb:Biotest_AG_(2022)
Talecris Biotherapeutics (2011)
Hologic's blood screening business (2017)
Nexelis (2022)
|
|
gptkbp:notableEvent
|
COVID-19 hyperimmune globulin development
|
|
gptkbp:notableInstitution
|
Grifols Plasma Logistics Center (Dublin, Ireland)
Grifols Innovation and New Technologies (Barcelona, Spain)
|
|
gptkbp:notableProduct
|
immune response
albumin
coagulation factors
|
|
gptkbp:number_of_plasma_donation_centers
|
over 390
|
|
gptkbp:numberOfEmployees
|
over 23,000
|
|
gptkbp:parentCompany
|
Grifols Bioscience
Grifols Diagnostic Solutions
Grifols Hospital
Grifols Plasma
|
|
gptkbp:products
|
diagnostic systems
hospital equipment
plasma-derived medicines
|
|
gptkbp:R&D_investment
|
over €300 million annually
|
|
gptkbp:revenue
|
€6.064 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:BME
|
|
gptkbp:stockSymbol
|
gptkb:GRF
|
|
gptkbp:subsidiary
|
gptkb:Talecris_Biotherapeutics
gptkb:Biotest_AG
|
|
gptkbp:ticker_symbol_(ADR)
|
GRFS
|
|
gptkbp:website
|
https://www.grifols.com
|
|
gptkbp:bfsParent
|
gptkb:Grifols
|
|
gptkbp:bfsLayer
|
8
|